Navigation Links
InnoPharma Completes $15 Million Series A Financing
Date:12/1/2011

PISCATAWAY, N.J., Dec. 1, 2011 /PRNewswire/ -- InnoPharma, Inc., a developer of sterile generic and specialty pharmaceutical products, announced that it has completed a $15 million Series A round of private financing. This financing was led by Thomas, McNerney & Partners.

"We are very pleased that InnoPharma's aggressive and well-managed growth over the last few years has allowed us to attract an outstanding investor, whose expertise and professional network will add tremendous value to InnoPharma," stated Navneet Puri, Ph.D., Founder, President, and Chief Executive Officer of InnoPharma. "The funds raised in this financing will allow us to accelerate the development of our product pipeline and also maximize the value that we offer to our customers and end users."

As a result of the financing, two new members have joined InnoPharma's board of directors: Alex Zisson and James Thomas, both partners at Thomas, McNerney & Partners.  The new board of directors will also include Navneet Puri, Raman Kapur, the former CEO of Warrick Pharmaceuticals, and Peter Werth, the CEO of ChemWerth.

"We're very excited to be partnering with InnoPharma.  The company's track record of FDA filings, approvals and partnerships is very impressive, and the additional resources will help InnoPharma maximize the true potential of its pipeline," said Alex Zisson.

Ledgemont Capital Group, LLC, served as the company's placement agent, and Lowenstein Sandler PC served as the company's legal counsel. Thomas, McNerney & Partners was represented by Goodwin Procter LLP.

About INNOPHARMA:

INNOPHARMA is a developer of sterile generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at www.innopharmallc.com.  

About Thomas, McNerney & Partners

Thomas, McNerney & Partners is a health care private equity firm that invests in life science and medical technology companies. Employing a multi-stage investment approach, Thomas, McNerney & Partners has $600 million in assets under management and provides seed and early stage funding to help entrepreneurs launch companies, as well as growth capital to emerging companies for furthering clinical development or for expansion of product commercialization. For more information, please visit: http://www.tm-partners.com/.


'/>"/>
SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. Agendia Successfully Completes Bi-Annual FDA Inspection
3. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
4. Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
5. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
6. Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
7. AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API
8. Peloton Therapeutics Completes $18 Million Series A Financing
9. Sinapis Pharma Completes Phase I Trial
10. MiMedx Group Completes $5,000,000 Private Placement
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 ... a leader in dairy research, today announced a new ... help reduce the chances that the global milk supply ... this dairy project, Cornell University has become the newest ... Food Supply Chain, a food safety initiative that includes ...
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
Breaking Biology News(10 mins):